Press release
Gaucher's Disease Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | CANbridge, AVROBIO, Graphite Bio, Sanofi, Orphazyme, Sanofi, Yuhan, Gain Therapeutics, M6P Therapeutics
"Gaucher's Disease Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Gaucher's Disease Therapeutics Market.
The report provides a detailed description of the Gaucher's Disease drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of Gaucher's Disease Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Gaucher's Disease Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Gaucher's Disease therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gaucher's Disease treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Gaucher's Disease drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Gaucher's Disease treatment market.
Learn More about the Clinical and Commercial Development Activities in the Gaucher's Disease Therapeutics Domain:
https://www.delveinsight.com/report-store/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Gaucher's Disease Therapeutics Analysis
There is no cure for Gaucher's Disease. However, enzyme replacement therapy and substrate reduction therapy are available to mitigate manifestations. Miglustat is the first oral agent for the treatment of individuals with mild to moderate Gaucher disease for whom ERT is not a therapeutic option.
The currently available recombinant glucocerebrosidase enzyme preparations are imiglucerase (CEREZYME); velalglucerase alfa (VPRIV); taliglucerase alfa (ELELYSO) and eliglustat (CERDELGA).
Growing awareness about Gaucher Disease and its treatment options, increasing R&D expenditures leading to high pipeline products, and an increase in the prevalence of Gaucher Diseases along with high unmet needs are the major factors that are supporting the growth of the Gaucher Disease therapeutics market globally.
To further improve the treatment scenario, there are approx. 14+ key companies developing therapies for Gaucher's Disease. Currently, AVROBIO is leading the therapeutics market with its Gaucher's Disease drug candidates in the most advanced stage of clinical development.
Gaucher's Disease Companies in the Therapeutics Market Include:
• CANbridge Life Sciences
• AVROBIO
• Gain Therapeutics
• M6P Therapeutics
• Denali Therapeutics
• Graphite Bio
• Sanofi
• Freeline Therapeutics
• Orphazyme
• Sanofi
• Prevail Therapeutics
• Yuhan
And Many Others
Emerging and Marketed Gaucher's Disease Therapies Covered in the Report Include:
• GPH301: Graphite Bio
• AVR-RD-02: AVROBIO
And Many More
Get an in-depth Assessment of the Emerging Therapies and Gaucher's Disease Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Gaucher's Disease Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Gaucher's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Request for Sample PDF to Understand More About the Gaucher's Disease Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Gaucher's Disease Current Treatment Patterns
4. Gaucher's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Gaucher's Disease Late-Stage Products (Phase-III)
7. Gaucher's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gaucher's Disease Discontinued Products
13. Gaucher's Disease Product Profiles
14. Gaucher's Disease Companies
15. Gaucher's Disease Drugs
16. Dormant and Discontinued Products
17. Gaucher's Disease Unmet Needs
18. Gaucher's Disease Future Perspectives
19. Gaucher's Disease Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gaucher's Disease Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | CANbridge, AVROBIO, Graphite Bio, Sanofi, Orphazyme, Sanofi, Yuhan, Gain Therapeutics, M6P Therapeutics here
News-ID: 3243947 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Gaucher
Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market - Restoring Bal …
Newark, New Castle, USA: The "Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Gaucher & Pompe Diseases Enzyme Replacement…
Gaucher Disease Treatment Market Size | Share | Growth Analysis 2022
The global gaucher disease treatment market size was valued at USD 1,522.3 million in 2021 and is poised to grow at a significant CAGR of 1.2% during the forecast period 2022-28. Gaucher disease is a rare genetic disorder that affects the body's ability to break down a certain type of fat called glucocerebroside. This build-up of fat can cause a range of symptoms, including enlarged organs, bone pain, anemia, and…
Gaucher Disease Treatment Market Size | Share | Growth Analysis 2022
The global gaucher disease treatment market size was valued at USD 1,522.3 million in 2021 and is poised to grow at a significant CAGR of 1.2% during the forecast period 2022-28. Gaucher disease is a rare genetic disorder that affects the body's ability to break down a certain type of fat called glucocerebroside. This build-up of fat can cause a range of symptoms, including enlarged organs, bone pain, anemia, and…
Gaucher Disease Market Revenue Data Historic and Forecast Analysis
The market for Gaucher disease was estimated at USD 980.0 million in 2021, and it is anticipated to grow at a CAGR of 8.5% to reach around USD 1,800.0 million in 2029.
The rising prevalence of Gaucher disease, increasing awareness about Gaucher disease, and upsurge in the number of approved therapies for the treatment of Gaucher disease. Even it is the most prevalent lysosomal storage disorder, Gaucher disease is a rare…
Gaucher Disease Market Size by 2025: QY Research
This recently published report examines the global Gaucher Disease market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Gaucher Disease market along with its drivers, restraints, and trends. It also classifies the market into different segments such…
Gaucher Disease Market Pharmaceuticals & Healthcare Analysis 2018 to 2025
In 2017, the global Gaucher Disease market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025.
Companies Mentioned are:
Sanofi, Shire, Actelion Pharma, Pfizer, ISU Pharm, ....
Sample/Inquiry at:
https://www.marketinsightsreports.com/reports/0905827183/global-gaucher-disease-market-size-status-and-forecast-2018-2025/inquiry?Source=openpr&mode=47
Further, the market is segmented based on the applications, types and Geography area such as
Gaucher Disease Market, by Types:
Enzyme Replacement Therapy
Substrate Reduction Therapy
Gaucher Disease Market, by Applications:
Non-Neuronopathic Gaucher Disease
Neuronopathic Gaucher Disease
Geographically,…
